PsyBio Therapeutics Corp.
PSYBF
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 25.00K | 12.50K | 0.00 | 12.50K | 25.00K |
| Gross Profit | -25.00K | -12.50K | 0.00 | -12.50K | -25.00K |
| SG&A Expenses | 132.00K | 701.70K | 711.20K | 810.20K | 1.15M |
| Depreciation & Amortization | -- | 38.00K | 38.00K | 38.00K | 38.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 157.00K | 752.20K | 901.20K | 863.60K | 1.35M |
| Operating Income | -157.00K | -752.20K | -901.20K | -863.60K | -1.35M |
| Income Before Tax | -182.00K | -811.50K | -941.60K | -921.90K | -1.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -182.00K | -811.50K | -941.60K | -921.90K | -1.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -182.00K | -811.50K | -941.60K | -921.90K | -1.44M |
| EBIT | -157.00K | -752.20K | -901.20K | -863.60K | -1.35M |
| EBITDA | -138.00K | -714.20K | -863.20K | -825.60K | -1.31M |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 128.18M | 128.18M | 111.33M | 111.34M | 111.89M |
| Average Diluted Shares Outstanding | 128.18M | 128.18M | 111.33M | 111.34M | 111.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |